Meloxicam oral suspension ( DrugBank: Meloxicam )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	2

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00034853 (ClinicalTrials.gov)	December 2000	2/5/2002	Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)	A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis	Arthritis, Juvenile Rheumatoid	Drug: meloxicam oral suspension;Drug: naproxen oral suspension	Boehringer Ingelheim	NULL	Completed	2 Years	17 Years	Both	180	Phase 3	United States;Brazil;Mexico;Ukraine;Argentina
2	NCT00279747 (ClinicalTrials.gov)	September 2000	19/1/2006	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.	Arthritis, Juvenile Rheumatoid	Drug: meloxicam 0.25 mg/kg;Drug: meloxicam 0.125 mg/kg;Drug: naproxen 10 mg/kg	Boehringer Ingelheim	NULL	Completed	2 Years	16 Years	Both	226	Phase 3	Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom